mevastatin has been researched along with Hyperlipoproteinemia Type II in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (72.22) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, V; Blom, DJ; Bourane, S; Cariou, B; Chemello, K; Croyal, M; Farnier, M; Lambert, G; Nativel, B; Pichelin, M; Raal, FJ; Ramin-Mangata, S; Tang, L; Thedrez, A | 1 |
| Blom, DJ; Chatelais, M; Gusarova, V; Lambert, G; Marais, AD; Passard, M; Petrides, F; Rye, KA; Sasiela, W; Schwahn, U; Thedrez, A | 1 |
| Haba, T; Koizumi, J; Mabuchi, H; Miyamoto, S; Sakai, Y; Takeda, R; Tatami, R; Wakasugi, T; Watanabe, A | 2 |
| Brown, MS; Goldstein, JL | 2 |
| De Boer, HH; Hendriks, T; Van Niekerk, JL | 1 |
| Matsuzawa, Y; Sudo, H; Yamamoto, A; Yamamura, T; Yokoyama, S | 1 |
| Hayashi, R; Hirobe, K; Kikkawa, T; Kishino, B; Matsuzawa, Y; Yamamoto, A | 1 |
| Koizumi, J; Mabuchi, H; Sakai, T; Sakai, Y; Takeda, R; Wakasugi, T; Watanabe, A; Yoshimura, A | 1 |
| Haba, T; Kametani, T; Koizumi, J; Mabuchi, H; Miyamoto, S; Takeda, R; Takeshita, H; Tatami, R; Ueda, K; Ueda, R; Wakasugi, T; Watanabe, A; Yoshimura, A | 1 |
| Mabuchi, H | 1 |
| Kuwano, M; Ono, M | 1 |
| Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S | 1 |
| Knight, BL; Patel, DD; Soutar, AK | 1 |
| Endo, A | 2 |
| Santafé Oroz, J; Segarra Domènech, J | 1 |
4 review(s) available for mevastatin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
The treatment of familial hypercholesterolaemia by partial ileal bypass surgery. A review of the literature.
Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Diarrhea; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Ileum; Lovastatin; Methods; Naphthalenes; Niacin; Postoperative Complications | 1984 |
[Clinical studies on hyperlipidemia].
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Blood Component Removal; Clinical Trials as Topic; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin | 1999 |
Somatic cell mutants of low density lipoprotein receptor.
Topics: Animals; Carbohydrate Sequence; Cell Line; Hyperlipoproteinemia Type II; Lovastatin; Molecular Sequence Data; Monensin; Mutation; Receptors, LDL | 1989 |
[Pharmacologic therapy of arteriosclerosis. II. New directions].
Topics: Animals; Anticholesteremic Agents; Arachidonate Lipoxygenases; Arteriosclerosis; Blood Platelets; Cholesterol; Cholesterol Esters; Cholesterol, LDL; Enzyme Induction; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoxygenase Inhibitors; Lovastatin; Male; Models, Biological; Muscle, Smooth, Vascular; Naphthalenes; Phosphatidylcholine-Sterol O-Acyltransferase; Platelet Aggregation; Rats; Receptors, LDL | 1985 |
1 trial(s) available for mevastatin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoprotein B-100; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Receptors, LDL; Serine Proteinase Inhibitors; Treatment Outcome; Young Adult | 2018 |
13 other study(ies) available for mevastatin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cells, Cultured; Fibroblasts; Flow Cytometry; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; Serine Endopeptidases | 2014 |
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
Topics: Anticholesteremic Agents; Coenzymes; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Ubiquinone | 2004 |
Lowering plasma cholesterol by raising ldl receptors. 1981.
Topics: Animals; Anticholesteremic Agents; Cholesterol; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Receptors, LDL | 2004 |
Lowering plasma cholesterol by raising LDL receptors.
Topics: Animals; Cholesterol; Dogs; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Middle Aged; Naphthalenes; Receptors, Cell Surface; Receptors, LDL | 1981 |
Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Homozygote; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Naphthalenes | 1984 |
Effects of probucol on homozygous cases of familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol; Energy Intake; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phenols; Plasma Exchange; Probucol; Skin Diseases; Tendons; Triglycerides; Xanthomatosis | 1983 |
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Drug Evaluation; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phospholipids; Triglycerides | 1983 |
Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Naphthalenes; Sterols | 1981 |
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Naphthalenes; Triglycerides; Ubiquinone | 1981 |
Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phenols; Plasmapheresis; Probucol; Xanthomatosis | 1986 |
Regulation of synthesis and cell content of the low-density-lipoprotein receptor protein in cultured fibroblasts from normal and familial hypercholesterolaemic subjects.
Topics: Acetates; Cell Membrane; Cells, Cultured; Cholesterol; Fibroblasts; Humans; Hyperlipoproteinemia Type II; Immunochemistry; Lipoproteins; Lovastatin; Methionine; Naphthalenes; Radioimmunoassay; Receptors, LDL | 1987 |
Drugs inhibiting HMG-CoA reductase.
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Chemical Phenomena; Chemistry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Naphthalenes; Sterols | 1985 |
HMG-CoA reductase inhibitors.
Topics: Animals; Cell Division; Cells, Cultured; Cholesterol; Drug Resistance; Enzyme Induction; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Naphthalenes; Structure-Activity Relationship | 1985 |